Diastolic heart failure
Therapeutic area
Cardiology
Rare disease
No
- Definition
- Heart failure caused by abnormal myocardial relaxation during diastole leading to defective cardiac filling.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Diastolic heart failure
- Alternative names
- diastolic heart failure
- Therapeutic area
- Cardiology
- All therapeutic areas
- Cardiology
- Severity
- Severe
- MONDO ID
- MONDO:0006727
- Parent condition
- MONDO:0005009
Related records
Broader conditions (7)
- Cardiovascular disorder
- Congestive heart failure
- Disease
- Disease by body system or component
- Heart disorder
- Heart failure
- Human disease
Trials (257)
- 2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
- A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers
- A Preliminary Study for INFORMED
- A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
- A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
- A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]
- A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
- A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure
- A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
- A Study of LY3971297 in Participants With Heart Failure
- A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure
- A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
- A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
- A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
- AB-1002 in Patients With Class III Heart Failure
- AI-based Echocardiographic Quantification in Heart Failure
- AI-based Echocardiography for Detection of Cardiac Amyloidosis
- AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices
- Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
- Aliskiren and Renin Inhibition in Diastolic Heart Failure
Drugs in development (14)
- Alagebrium Phase 2
- Dapagliflozin Phase 2
- Ivabradine Phase 2
- Metoprolol Phase 2
- Perhexiline Phase 2
- Potassium chloride Phase 2
- Potassium nitrate Phase 2
- Ranolazine Phase 2
- Ribose (pyranose) Phase 2
- Sildenafil Phase 3
- Sitaxentan sodium Phase 2
- Spironolactone Phase 3
- Ubidecarenone Phase 2
- Udenafil Phase 3
Other linked drugs (4)
- Aliskiren
- Atorvastatin
- Eplerenone
- Lisinopril